Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

Treatment with camrelizumab combined with apatinib demonstrates improvements in overall survival (OS), progression-free survival (PFS), and response rates in patients with esophageal squamous cell carcinoma (ESCC), a study has shown.

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

08 Jul 2026

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

In vitro exposure to acid-suppressive medications does not appear to be associated with an increased risk of inflammatory bowel disease (IBD) development in offspring, as shown in a nationwide cohort study.

No clear link between prenatal acid suppressant use and IBD in offspring

07 Jul 2026

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

07 Jul 2026

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

07 Jul 2026

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

06 Jul 2026

Anticoagulants up risk of bleeding after esophageal dilation procedure

06 Jul 2026

Patients taking anticoagulant medications at the time of esophageal dilation are at increased risk of experiencing gastrointestinal bleeding after the procedure, suggests a study.

Anticoagulants up risk of bleeding after esophageal dilation procedure

06 Jul 2026

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

A recent study suggests that time-restricted eating (TRE) may help reduce weight and improve cardiometabolic health by regulating gut microbiota and serum metabolites.

Time-restricted eating reshapes gut microbiota to induce weight loss

04 Jul 2026

Adjunctive GLP-1 RA treatment of limited benefit in stable IBD patients with obesity, diabetes

01 Jul 2026

In patients with stable inflammatory bowel disease (IBD) receiving advanced therapies who have comorbid obesity and/or diabetes, adjunctive treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide or tirzepatide does not appear to improve clinical outcomes, according to new research.